General
AstraZeneca says its coronavirus vaccine can stop severe disease despite ‘limited’ success against South African variant
British company AstraZeneca says it believes its COVID-19 vaccine developed with Oxford University can protect against severe disease caused by the South African variant of the virus.
Key points:
- Around 2,000 people took part in the trial
- None of the participants were hospitalised or died after receiving the vaccine
- But it showed “limited efficacy” against mild disease due to the South African variant
But AstraZeneca confirmed that early data from a small trial had shown only limited efficacy for the vaccine against mild disease primarily due to this variant.
“We do believe our vaccine could protect against severe disease, as neutralising antibody activity is equivalent to that of other COVID-19 vaccines that have demonstrated activity…
-
General21 hours agoIf Iran’s regime fell tomorrow, Iranians wouldn’t be united on what comes next
-
General19 hours agoInjured former Greens candidate Hannah Thomas charged with hindering or resisting police at pro-Palestinian protest
-
General18 hours agoTony Burke’s detention inaction | The Spectator Australia
-
General13 hours agoAustralian workers lose more than $4.7 billion a year in unpaid super — and the ATO rarely penalises employers